Lymphatica Medtech raises EUR 17.9M in Series B to advance Lymphedema treatment

08.10.2024 16:00, Rita Longobardi

Clinical-stage Lymphatica Medtech based in Lausanne has raised EUR 17.9 million in Series B funding to accelerate the development and validation of LymphoDrain, an innovative implantable device for treating lymphedema. The minimally invasive solution aims to restore lymphatic function and improve the quality of life for millions affected by this chronic condition, which currently has no cure.

Lymphatica Medtech, a Swiss MedTech company developing innovative treatments for lymphedema, has raised EUR 17.9 million in a Series B round. The funding will support the continued development and commercialization of its implantable lymphatic bypass system.

The funding round was co-led by Panakès Partners, TechWald Next S.p.A., and CDP Venture Capital’s Digital Transition Fund, with contributions from OCCIDENT, Zürcher Kantonalbank, and Club Degli Investitori. Existing investors, including High-Tech Gründerfonds (HTGF), also participated.

In line with its growth strategy, Lymphatica has established a subsidiary in Italy to enhance its R&D capabilities and oversee manufacturing and clinical operations.

The company's leadership has been further bolstered by the appointment of Dan Rose as the new Chairman of the Board. Rose brings significant experience from LimFlow (acquired by Inari Medical), Direct Flow Medical, Sequana Medical, and Medtronic. Additionally, Alessio Beverina, Managing Partner at Panakès, and Lukas Guenther, Chief Investment Officer at TechWald Next, have joined the Board of Directors, along with existing independent board member Nanci Govinder.

Lymphatica Medtech participated in Venture Leaders Medtech in 2021 and Venture Leaders China in 2019, and won the final stage of Venture Kick in 2017.


Lymphatica Medtech Co-Founders: COO Valentina Triacca and CEO Marco Pisano